ROR2 knockdown suppresses breast cancer growth through PI3K/ATK signaling.
Animals
Breast
/ metabolism
Breast Neoplasms
/ genetics
Cell Line, Tumor
Female
Gene Knockdown Techniques
Humans
Mice
Mice, Inbred BALB C
Middle Aged
Phosphatidylinositol 3-Kinases
/ genetics
Proto-Oncogene Proteins c-akt
/ genetics
Receptor Tyrosine Kinase-like Orphan Receptors
/ genetics
Signal Transduction
/ genetics
PI3K/AKT signaling
ROR2
apoptosis
breast cancer cell
proliferation
Journal
Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617
Informations de publication
Date de publication:
02 07 2020
02 07 2020
Historique:
received:
17
01
2020
accepted:
25
05
2020
pubmed:
3
7
2020
medline:
17
3
2021
entrez:
3
7
2020
Statut:
ppublish
Résumé
The receptor tyrosine kinase like orphan receptor 2 (ROR2) has been implicated in the pathogenesis of a variety of human cancers, including breast cancer. Here, we analyzed the clinical significance of ROR2 in breast cancer (BC) progression, and its function in the regulation of BC cell proliferation and growth. Analysis of
Identifiants
pubmed: 32614787
pii: 103400
doi: 10.18632/aging.103400
pmc: PMC7377870
doi:
Substances chimiques
ROR2 protein, human
EC 2.7.10.1
Receptor Tyrosine Kinase-like Orphan Receptors
EC 2.7.10.1
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13115-13127Références
Pediatr Hematol Oncol. 2019 Sep;36(6):352-364
pubmed: 31441359
Adv Exp Med Biol. 2018;1110:35-53
pubmed: 30623365
Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):335-42
pubmed: 24650973
J Cancer Res Clin Oncol. 2015 Feb;141(2):243-54
pubmed: 25209439
Cell Biochem Funct. 2017 Jun;35(4):217-231
pubmed: 28498520
J Cancer Res Ther. 2014 Jul-Sep;10(3):506-11
pubmed: 25313729
Leukemia. 2020 Jan;34(1):257-270
pubmed: 31148590
World J Gastroenterol. 2012 Mar 28;18(12):1328-38
pubmed: 22493546
Oncotarget. 2015 Sep 22;6(28):24912-21
pubmed: 26305508
Development. 2016 Sep 1;143(17):3182-94
pubmed: 27578181
Oncogene. 2010 Jan 7;29(1):34-44
pubmed: 19802008
Biosci Rep. 2017 Nov 29;37(6):
pubmed: 29054966
Cell. 2012 Feb 3;148(3):409-20
pubmed: 22304912
J Biol Chem. 2003 Aug 1;278(31):29057-64
pubmed: 12754255
World J Gastroenterol. 2017 Apr 14;23(14):2601-2612
pubmed: 28465645
PeerJ. 2018 Nov 9;6:e5917
pubmed: 30515357
Oncol Res. 2017 Jan 26;25(2):195-205
pubmed: 28277191
Curr Med Chem. 2011;18(18):2715-26
pubmed: 21649579
Cancer Discov. 2013 Dec;3(12):1378-93
pubmed: 24104062
Mol Cancer. 2010 Jun 30;9:170
pubmed: 20591152
Cancer Lett. 2012 Jan 28;314(2):244-55
pubmed: 22056813
Front Oncol. 2017 Jun 26;7:135
pubmed: 28695110
Int J Obes (Lond). 2018 Mar;42(3):334-343
pubmed: 29151594
Int J Clin Exp Pathol. 2015 Jan 01;8(1):856-61
pubmed: 25755786
Oncogene. 2009 Jul 9;28(27):2513-23
pubmed: 19448672
Expert Rev Mol Med. 2012 Jan 11;14:e1
pubmed: 22233681
Pharmacol Ther. 2015 Jun;150:143-8
pubmed: 25614331